

## Consultation

### Impact of WHO-endorsed molecular diagnostics on TB and MDR-TB case- and treatment outcome definitions

Date: 12-13 May

Venue: Room HTM 65, WHO Headquarters, Geneva, Switzerland

#### Background

In December 2010, WHO endorsed the Xpert MTB/RIF molecular assay and recommended that roll-out of the technology be phased in by country health authorities within the context of national plans for appropriate management of TB, MDR-TB and HIV-associated TB. A Global Consultation subsequently convened by WHO outlined consensus on interim diagnostic algorithms, patient management approaches, and operational/logistical aspects to be addressed during Xpert MTB/RIF implementation. These aspects are contained in a Rapid Implementation document recently issued by WHO, aimed at guiding systematic roll-out of Xpert MTB/RIF in varying epidemiological and resource settings, with a view towards large-scale implementation based on programmatic data collected during the roll-out phase.

TB and MDR-TB case- and treatment outcome definitions currently rely on bacteriological confirmation using microscopy, culture and DST results, and clinical decision to treat. The addition of WHO-endorsed molecular tests (Xpert MTB/RIF and line probe assays) as stand-alone diagnostic tests do not readily fit into existing WHO recording and reporting systems. Consequently, there is a need to review current TB and MDR-TB case- and outcome definitions and assess the anticipated impact of these new molecular tests on surveillance and on current WHO recording and reporting systems. WHO is therefore convening a small, focused consultation with prominent technical partners and agencies active in TB and MDR-TB management and control.

The overall goal of the consultation is to discuss and refine current TB and MDR-TB case- and treatment outcome definitions, especially in anticipation of widespread use of the Xpert MTB/RIF assay. Outcomes from this consultation will be presented to the WHO Strategic and Technical Advisory Group for TB (STAG-TB) for consideration at the annual STAG-TB meeting in June 2011.

#### Meeting objectives

- To review and propose refinements to current TB and MDR-TB case definitions;
- To review and propose refinements to current TB and MDR-TB treatment outcome definitions.

#### Expected outcomes

Agreement on a proposed set of TB and MDR-TB case- and treatment outcome definitions that complement existing WHO guidelines, for consideration at the June 2011 STAG-TB meeting.

#### Participants

The meeting will include representatives from leading international institutions and agencies providing countries with expertise in TB and MDR-TB programmatic management and control, country representatives, and individuals involved in global surveillance activities.

## DRAFT AGENDA

**Day 1: 12 May 2011**

*Chair: Karin Weyer*

9:00-9:10	Welcome	Mario Raviglione WHO
9:10-9:25	Meeting objectives	Katherine Floyd WHO
9:25-9:45	Overview of rapid TB tests - WHO-endorsed and those in the pipeline	Karin Weyer WHO
9:45-10:00	Overview of current TB case- and treatment outcome definitions	Malgosia Grzemska WHO
10:00-11:30	Overview of current MDR-TB case and treatment outcome definitions	Dennis Falzon WHO
11:30-11:00	<i>Coffee break</i>	
11:00-12:00	Revising case definitions in the context of WHO-endorsed rapid tests: Options and implications*	Philippe Glaziou WHO
12:00-13:00	Facilitated discussion on options and implications: non-MDR-TB	Eugene McCray CDC
13:00-14:00	<i>Lunch</i>	
14:00-15:00	Facilitated discussion on options and implications: MDR-TB	Chen Yuan Chiang The Union
15:00-15:30	Proposed set of case definitions: non-MDR- TB	Philippe Glaziou WHO
15:30-16:00	Discussion and final consensus	Eugene McCray CDC
16:00-16:30	<i>Coffee break</i>	
16:30-17:00	Proposed set of case definitions: MDR-TB	Dennis Falzon WHO
17:00-18:00	Discussion and final consensus	Chen Yuan Chiang The Union
18:00	<b>Cocktail reception</b>	

**Day 2: 13 May 2011**

*Chair: Katherine Floyd*

9:00-9:30	Revising treatment outcome definitions in the context of WHO-endorsed rapid tests: Options and implications*	Philippe Glaziou WHO
9:30-10:30	Facilitated discussion on options and implications: non- MDR- TB	Christy Hanson USAID
10:30-11:00	<i>Coffee break</i>	
11:00-12:30	Facilitated discussion on options and implications: MDR-TB	Aamir Khan MDR-TB WG
12:30-13:30	<i>Lunch</i>	
13:30-14:00	Proposed set of treatment outcome definitions: non-MDR-TB	Philippe Glaziou WHO
14:00-14:30	Discussion and final consensus	Christy Hanson USAID
14:30-15:00	Proposed set of treatment outcome definitions: MDR-TB	Dennis Falzon WHO
15:00-15:30	Discussion and final consensus	Aamir Khan MDR-TB WG
15:30-16:00	<i>Coffee break</i>	
16:00-16:30	Summary and next steps	Katherine Floyd WHO
16:30-17:00	<i>Closing</i>	Mario Raviglione WHO

\*A Discussion Paper will be circulated in advance of the meeting